ABK Biomedical Revenue and Competitors

Halifax,

Location

#8359

Growjo Ranking

Estimated Revenue & Valuation

  • ABK Biomedical's estimated annual revenue is currently $5.1M per year.(i)
  • ABK Biomedical's estimated revenue per employee is $125,500
  • ABK Biomedical's total funding is $79M.

Employee Data

  • ABK Biomedical has 41 Employees.(i)
  • ABK Biomedical grew their employee count by 3% last year.

ABK Biomedical's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
VP Clinical Development & Regulatory AffairsReveal Email/Phone
3
VP R&D and Nuclear OperationsReveal Email/Phone
4
Director, Product and Program ManagementReveal Email/Phone
5
Director EngineeringReveal Email/Phone
6
Regulatory Affairs DirectorReveal Email/Phone
7
Co-Founder and Director for Biomaterials R&DReveal Email/Phone
8
Chief Business OfficerReveal Email/Phone
9
Chief Financial OfficerReveal Email/Phone
10
Director, Clinical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is ABK Biomedical?

Combining a compelling clinical market with innovative biomaterials invented by Drs Bob Abraham, Daniel Boyd and Sharon Kehoe, The Three Founders saw the opportunity to transform an interventional radiology procedure called embolization

keywords:N/A

$79M

Total Funding

41

Number of Employees

$5.1M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ABK Biomedical News

2022-04-17 - Tris Acryl Gelatin Microspheres Market to witness Growth ...

Merit Medical, Sirtex Medical, ABK Biomedical, Young Pharmaceuticals. Global Tris Acryl Gelatin Microspheres Market Segmentation: Market...

2019-04-08 - ABK Biomedical Raises $30M in Series B Funding

ABK Biomedical, Inc., a Halifax, Nova Scotia, Canada-based medical device company dedicated to the research, development and commercialization of innovative embolic therapies, raised $30m in Series B funding. The round was co-led by F-Prime Capital and Varian Medical Systems. The company will ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.6M42-5%N/A
#2
N/A4476%N/A
#3
N/A45-8%N/A
#4
$5.5M4712%N/A
#5
$3.5M4812%N/A